David Rubin to Randomized Controlled Trials as Topic
This is a "connection" page, showing publications David Rubin has written about Randomized Controlled Trials as Topic.
Connection Strength
1.541
-
Inclusion of Under-represented Racial and Ethnic Minorities in Randomized Clinical Trials for Inflammatory Bowel Disease. Gastroenterology. 2022 01; 162(1):17-21.
Score: 0.502
-
Patient-Reported Outcomes in Clinical Trials of Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol. 2026 Oct; 24(10):2650-2670.
Score: 0.174
-
Time to rethink washout periods in inflammatory bowel disease clinical trials: an international Delphi consensus. J Crohns Colitis. 2026 May 08; 20(5).
Score: 0.173
-
Integrated long-term safety of 10-year ozanimod treatment: results from clinical trials in patients with moderate-to-severe ulcerative colitis or relapsing multiple sclerosis. Inflamm Bowel Dis. 2026 May 01; 32(5):954-962.
Score: 0.173
-
An International Consensus on Appropriate Management of Corticosteroids in Clinical Trials in Inflammatory Bowel Disease. Gastroenterology. 2025 11; 169(6):1282-1293.
Score: 0.162
-
Histologic Remission in Ulcerative Colitis: Are We There Yet? Am J Gastroenterol. 2019 05; 114(5):713-715.
Score: 0.106
-
Evaluating treatment to a target of transmural healing in patients with moderately to severely active Crohn's disease: rationale, design and protocol for the randomised controlled VECTORS trial. BMJ Open Gastroenterol. 2026 Feb 20; 13(1).
Score: 0.043
-
Cardiovascular events observed among patients in the etrasimod clinical programme: an integrated safety analysis of patients with moderately to severely active ulcerative colitis. BMJ Open Gastroenterol. 2025 Jan 08; 12(1).
Score: 0.039
-
Analysis of Clinical Trial Screen Failures in Inflammatory Bowel Diseases [IBD]: Real World Results from the International Organization for the study of IBD. J Crohns Colitis. 2024 Apr 23; 18(4):548-559.
Score: 0.038
-
Opportunistic Infections in Patients with Inflammatory Bowel Disease Treated with Advanced Therapies: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Crohns Colitis. 2023 Mar 18; 17(2):199-210.
Score: 0.035
-
CORE-IBD: A Multidisciplinary International Consensus Initiative to Develop a Core Outcome Set for Randomized Controlled Trials in Inflammatory Bowel Disease. Gastroenterology. 2022 10; 163(4):950-964.
Score: 0.033
-
Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists. Clin Gastroenterol Hepatol. 2017 02; 15(2):229-239.e5.
Score: 0.022
-
Reinduction with Certolizumab Pegol in Patients with Crohn's Disease Experiencing Disease Exacerbation: 7-Year Data from the PRECiSE 4 Study. Inflamm Bowel Dis. 2016 08; 22(8):1870-80.
Score: 0.022
-
Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares. Aliment Pharmacol Ther. 2009 Feb 01; 29(3):247-57.
Score: 0.013
-
Treatment of anal fissures with topical nitroglycerin. Expert Opin Pharmacother. 2001 Jan; 2(1):41-5.
Score: 0.007